BioCentury | Aug 5, 2020
Product Development

I-SPY COVID brings new set of targets to master protocols for acute respiratory distress

While most master protocols for COVID-19 have converged on an overlapping set of experimental therapies, the COVID R&D Alliance’s adaptive trial is kicking off with five therapeutic targets largely untouched in the indication. Three members...
BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
BioCentury | Mar 22, 2019
Financial News

Spinal cord injury company NervGen raises $10M IPO

NervGen Pharma raised $10 million in an IPO on TSX Ventures on March 13. It plans to submit an IND late this year for lead candidate, NVG-291, to treat spinal cord injury and peripheral nerve...
BioCentury | Oct 31, 2018
Distillery Techniques


TECHNOLOGY: Plasma markers The numbers of circulating hybrid leukocyte-epithelial cells expressing PTPRC and creatine kinase could help predict survival in pancreatic cancer. In 18 patients, high numbers of the hybrid cells expressing PTPRC and creatine...
BioCentury | Oct 31, 2018
Distillery Therapeutics


INDICATION: Addiction In vitro and mouse studies identified an illudalic acid-based PTPRD inhibitor that could help treat cocaine addiction. In a mouse model of cocaine addiction, heterozygous knockout of PTPRD decreased cocaine self-administration compared with...
BioCentury | Oct 11, 2018
Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Mouse studies suggest PTPRS mimetics could help treat MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, a small peptide mimetic of PTPRS decreased clinical disease scores, demyelinated spinal...
BioCentury | Jun 22, 2018
Targets & Mechanisms

T cell balancing act

Among the improvements to next-generation CAR T cell therapies is the need to optimize the ratios of the different T cell subsets. While CD8 + T cells have grabbed most of the attention, a study...
BioCentury | May 23, 2018
Distillery Therapeutics


INDICATION: Colorectal cancer Patient sam/ple and cell culture studies suggest inhibiting DEPTOR could help treat colorectal cancer. In samples of colorectal tumors and the surrounding mucosa from patients, DEPTOR expression was higher than in normal...
BioCentury | Jan 4, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: December 2017

New Therapeutic Targets and Biomarkers: December 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during December 2017. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Jan 2, 2018
Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy Non-immune cells engineered with synthetic circuits to produce cytotoxic output in response to tumor antigens could help treat cancer. The method involves engineering HEK cells or human mesenchymal stem cell (MSC) lines...
Items per page:
1 - 10 of 45